Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) EBITDA per Share: ¥3.35 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥38.88
GF Value ¥40.64
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co EBITDA per Share?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 -1.32% 94 EBITDA per Share is ¥3.35 as of Mar. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 94/100 and a GF Value™ of ¥40.64 (Fairly Valued). The stock has 2 warning signs investors should review. Among 813 Drug Manufacturers companies, Tibet Rhodiola Pharmaceutical Holding Co ranks better than 76.88% on this metric.

Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share for the three months ended in Mar. 2026 was ¥1.02. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.35.

During the past 12 months, the average EBITDA per Share Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was -2.90% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 27.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 25.90% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share or its related term are showing as below:

SHSE:600211' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21.1   Med: 14.25   Max: 86.4
Current: 27.5

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 86.40% per year. The lowest was -21.10% per year. And the median was 14.25% per year.

SHSE:600211's 3-Year EBITDA Growth Rate is ranked better than
76.88% of 813 companies
in the Drug Manufacturers industry
Industry Median: 8.9 vs SHSE:600211: 27.50

Tibet Rhodiola Pharmaceutical Holding Co's EBITDA for the three months ended in Mar. 2026 was ¥327 Mil.

During the past 12 months, the average EBITDA Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was -2.80% per year. During the past 3 years, the average EBITDA Growth Rate was 27.50% per year. During the past 5 years, the average EBITDA Growth Rate was 25.90% per year. During the past 10 years, the average EBITDA Growth Rate was 20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 93.80% per year. The lowest was -21.80% per year. And the median was 15.40% per year.


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Tibet Rhodiola Pharmaceutical Holding Co EBITDA per Share Related Terms


Tibet Rhodiola Pharmaceutical Holding Co EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co EBITDA per Share Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.70 3.03 3.84 3.51

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 1.04 0.54 0.75 1.02
SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=1132.738/322.313
=3.51

Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=326.787/321.193
=1.02

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of ¥3.35 mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a EBITDA per Share of ¥3.35 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #188 out of 813 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share too high?
Tibet Rhodiola Pharmaceutical Holding Co's current EBITDA per Share is ¥3.35. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #188 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's EBITDA per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #188 out of 813 companies for EBITDA per Share. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current EBITDA per Share is ¥3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.64, compared to a current price of ¥38.88 — trading 4.3% below its estimated fair value. The current EBITDA per Share is ¥3.35. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current EBITDA per Share is ¥3.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥38.88 is trading 4.3% below its estimated GF Value™ of ¥40.64. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • EBITDA per Share: ¥3.35
  • GF Value™: ¥40.64 vs. price of ¥38.88 (4.3% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.88
Price
¥40.64
GF Value